PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

279

Participants

Timeline

Start Date

May 14, 2013

Primary Completion Date

May 1, 2018

Study Completion Date

September 26, 2018

Conditions
Metastatic Pancreatic Cancer
Interventions
DRUG

PEGPH20

PEGPH20 will be administered as per the dose and schedule specified in the respective arms.

DRUG

Nab-paclitaxel

Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms.

DRUG

Gemcitabine

Gemcitabine will be administered as per the dose and schedule specified in the respective arms.

DRUG

Dexamethasone

Dexamethasone will be administered as per the dose and schedule specified in the respective arms.

DRUG

Enoxaparin

Enoxaparin will be administered as per the dose and schedule specified in the respective arms.

Trial Locations (51)

10029

Mount Sinai Medical Center, New York

10032

Columbia University Medical Center, New York

11042

North Shore Long Island Jewish Health System, Lake Success

14263

Roswell Park Cancer Institute, Buffalo

14642

University of Rochester, Rochester

15213

UPMC Cancer Center, Pittsburgh

20007

Georgetown University Medical Center, Washington D.C.

21231

Johns Hopkins University Hospital, Baltimore

29605

Greenville Health System, Greenville

30318

Piedmont Hospital, Atlanta

33136

University of Miami, Sylvester comprehensive Cancer Center, Miami

33612

H. Lee Moffit Cancer Center, Tampa

35213

Alabama Oncology, Birmingham

36604

University of South Alabama Mitchell Cancer Institute, Mobile

40202

Norton Cancer Institute - Norton HealthCare Pavilion, Louisville

44718

Gabrail Cancer Center, Canton

48109

University of Michigan, Ann Arbor

53226

Froedtert Hospital, Medical College of Wisconsin, Milwaukee

53792

University of Wisconsin Hospitals and Clinics, Madison

55407

Virginia Piper Cancer Institute, Minneapolis

55455

Unniversity of Minnesota, Minneapolis

60153

Loyola University Medical Center, Maywood

63110

Washington University School of Medicine, St Louis

64132

Research Medical Center, Kansas City

72703

Highlands Oncology Group, Fayetteville

73104

University of Oklahoma Health Science Center, Oklahoma City

75246

Texas Oncology - Baylor, Dallas

75702

Texas Oncology, Tyler

78130

Cancer Care Centers of South Texas, New Braunfels

80045

University of Colorado Cancer Center, Aurora

80218

Rocky Mountain Cancer Center, Denver

85234

Banner MD Anderson Cancer Center, Gilbert

85259

Mayo Clinic - Scottsdale, Scottsdale

85704

Arizona Oncology Associates, PC, Tucson

89169

Comprehensive Cancer Centers of Nevada, Las Vegas

90048

Cedars-Sinai Medical Center, Los Angeles

90603

The Oncology Institute of Hope and Innovation, Whittier

91505

Providence St Joseph Medical Center, Burbank

92037

Scripps Cancer Center, La Jolla

92093

UCSD - Moore's Cancer Center, La Jolla

92868

University of California Medical Center, Orange

94115

Pacific Hematology Oncology Associates, San Francisco

94574

Saint Helena Hospital, St. Helena

98109

Seattle Cancer Care Alliance, Seattle

98405

NorthWest Medical Specialties, PLLC, Tacoma

99336

Columbia Basin Hematology and Oncology, Kennewick

06902

Stamford Hospital, Stamford

02215

Beth Israel Deaconess Medical Center, Boston

01805

Lahey Clinic, Burlington

01655

University of Mass Medical School, Worcester

07503

St. Joseph's Regional Medical Center, Paterson

Sponsors
All Listed Sponsors
lead

Halozyme Therapeutics

INDUSTRY

NCT01839487 - PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer | Biotech Hunter | Biotech Hunter